{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:35:17Z","timestamp":1707525317693},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,11]]},"DOI":"10.7759\/cureus.46858","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T18:44:35Z","timestamp":1697049875000},"source":"Crossref","is-referenced-by-count":0,"title":["The First Case of Daratumumab-Induced Fulminant Hepatic Failure"],"prefix":"10.7759","author":[{"given":"Ali Tariq","family":"Alvi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin","family":"George Mathew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murali","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0229","article-title":"FDA approval summary: daratumumab for treatment of multiple myeloma after one prior therapy","volume":"22","author":"Bhatnagar V","year":"2017","unstructured":"Bhatnagar V, Gormley NJ, Luo L, et al.. FDA approval summary: daratumumab for treatment of multiple myeloma after one prior therapy. Oncologist. 2017, 22:1347-53. 10.1634\/theoncologist.2017-0229","journal-title":"Oncologist"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00143","article-title":"Managing infusion reactions to new monoclonal antibodies in multiple myeloma: daratumumab and elotuzumab","volume":"14","author":"Nooka AK","year":"2018","unstructured":"Nooka AK, Gleason C, Sargeant MO, Walker M, Watson M, Panjic EH, Lonial S. Managing infusion reactions to new monoclonal antibodies in multiple myeloma: daratumumab and elotuzumab. J Oncol Pract. 2018, 14:414-22. 10.1200\/JOP.18.00143","journal-title":"J Oncol Pract"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22177","article-title":"Acute liver failure: summary of a workshop","volume":"47","author":"Lee WM","year":"2008","unstructured":"Lee WM, Squires RH Jr, Nyberg SL, Doo E, Hoofnagle JH. Acute liver failure: summary of a workshop. Hepatology. 2008, 47:1401-15. 10.1002\/hep.22177","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1503","article-title":"Drug-induced liver Injury in GI practice","volume":"4","author":"Sandhu N","year":"2020","unstructured":"Sandhu N, Navarro V. Drug-induced liver Injury in GI practice. Hepatol Commun. 2020, 4:631-45. 10.1002\/hep4.1503","journal-title":"Hepatol Commun"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo A","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, et al.. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016, 375:754-66. 10.1056\/NEJMoa1606038","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31894-X","article-title":"Acute liver failure","volume":"394","author":"Stravitz RT","year":"2019","unstructured":"Stravitz RT, Lee WM. Acute liver failure. Lancet. 2019, 394:869-81. 10.1016\/S0140-6736(19)31894-X","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7326\/M15-2211","article-title":"Outcomes in adults with acute liver failure between 1998 and 2013: an observational cohort study","volume":"164","author":"Reuben A","year":"2016","unstructured":"Reuben A, Tillman H, Fontana RJ, et al.. Outcomes in adults with acute liver failure between 1998 and 2013: an observational cohort study. Ann Intern Med. 2016, 164:724-32. 10.7326\/M15-2211","journal-title":"Ann Intern Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.03.006","article-title":"Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study","volume":"148","author":"Chalasani N","year":"2015","unstructured":"Chalasani N, Bonkovsky HL, Fontana R, et al.. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015, 148:1340-52.e7. 10.1053\/j.gastro.2015.03.006","journal-title":"Gastroenterology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.12.016","article-title":"Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study","volume":"152","author":"Nicoletti P","year":"2017","unstructured":"Nicoletti P, Aithal GP, Bjornsson ES, et al.. Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study. Gastroenterology. 2017, 152:1078-89. 10.1053\/j.gastro.2016.12.016","journal-title":"Gastroenterology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20800","article-title":"Outcome and prognostic markers in severe drug-induced liver disease","volume":"42","author":"Bj\u00f6rnsson E","year":"2005","unstructured":"Bj\u00f6rnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005, 42:481-9. 10.1002\/hep.20800","journal-title":"Hepatology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23577","article-title":"Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method","volume":"51","author":"Rockey DC","year":"2010","unstructured":"Rockey DC, Seeff LB, Rochon J, et al.. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010, 51:2117-26. 10.1002\/hep.23577","journal-title":"Hepatology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/195106-the-first-case-of-daratumumab-induced-fulminant-hepatic-failure","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:10:36Z","timestamp":1707509436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/195106-the-first-case-of-daratumumab-induced-fulminant-hepatic-failure"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,11]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.46858","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,11]]}}}